What's New at The Body
HIV/AIDS News You Can Use
September 24, 2003
Looking for more research updates from ICAAC 2003? This e-mail contains several more highlights from the conference we covered last week, and dozens of additional summaries are available on our site. Visit our ICAAC 2003 page for a full rundown.read this fact sheet from New Mexico AIDS InfoNet. It provides an overview of the situations and behaviors that can increase your risk of contracting HIV. once-weekly epoetin alfa (Procrit), used to treat anemia, found promising signs that administering one dose of the drug every two weeks could be just as effective as once-weekly or thrice-weekly dosing schedules. Robert Frascino, M.D., reports. do not disclose their HIV status to their casual sex partners, according to a recent study. discussion on structured treatment interruptions that took place at this summer's International AIDS Society conference.
For more on treatment interruptions, read through The Body's collection of articles.the more likely they were to have low bone density, regardless of the HIV meds they have or haven't taken. taking their first HAART regimens, treatment regimens containing efavirenz (Sustiva), lopinavir/ritonavir (Kaletra) or nevirapine (Viramune) were found to be more potent than regimens containing boosted indinavir (Crixivan) or nelfinavir (Viracept). Gerald Pierone, Jr., M.D., reports from ICAAC 2003. law that makes it a crime to intentionally infect a sexual partner with HIV, the San Francisco Chronicle reports. antiretroviral use significantly increased the risk of premature delivery and reversible anemia. confirmed the results of ACTG 5095, a study that found that Trizivir (AZT + 3TC + abacavir) was not quite as potent as the efavirenz (Sustiva)- or nevirapine (Viramune)-containing regimens for initial therapy. Andrew Pavia, M.D., reports from ICAAC 2003. help healthcare workers determine the best time to start treating people with HIV and what to start treatment with. Judy Aberg, M.D., reports from ICAAC 2003 on a symposium reviewing the guidelines' most important revisions. How do you get herpes? Is there a cure? Does herpes pose a health risk for people with HIV? What's the difference between genital herpes and the herpes sores you get on your mouth? This fact sheet from New Mexico AIDS InfoNet has the answers. Read this update from the AIDS Vaccine 2003 Conference, which took place last week in New York.
Want to take a closer look at the research presented at this conference? The AIDS Vaccine 2003 Conference Web site allows you to browse the abstracts of many conference presentations.developing HIV protease inhibitor 908 (GW433908, fosamprenavir) and other medications were presented at ICAAC 2003. Edwin DeJesus, M.D., reports on their findings, including those highlighting the drug's interaction with Kaletra, antacids and atorvastatin (Lipitor), which is used to treat high cholesterol. newly approved once-a-day NRTI FTC (emtricitabine, Emtriva) appears to interact safely with AZT (zidovudine, Retrovir) and tenofovir (Viread), according to the results of short-term studies in HIV-negative people. Andrew Pavia, M.D., reports from ICAAC 2003. resistance testing and therapeutic drug monitoring are crucial tools to manage HIV-positive people who are treatment naive as well as those who are treatment experienced. Mark Holodniy, M.D., explains why.
Starting HAART at Low CD4 Count Can Mean That Functional Immune Response Is Blunted
New research supports an opinion held by many healthcare workers that treatment should be started before a person's CD4 count drops below the 250 mark
From aidsmap.com (September 23, 2003)
Women Living With HIV Caring for Each Other
HIV-positive women in Botswana have created an innovative support network through which newly diagnosed women receive individual care and companionship from other women living with the virus
From UN Integrated Regional Information Networks (September 23, 2003)
Countries Receive a Low Score From the UN in Fight Against AIDS
A new United Nations report gives no country an A; though many countries have some sort of comprehensive prevention, education or treatment strategy, the report says that ignorance and stigma still run high and that far more money is needed
From The New York Times (September 22, 2003)
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States
These updated guidelines include this year's newly approved antiretrovirals
From HIV/AIDS Treatment Information Service (September 22, 2003)
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection
When HIV-positive people on successful treatment switched their protease inhibitor to abacavir (Ziagen), their risk of treatment failure increased, this study found -- although significantly fewer people on abacavir had to stop therapy due to side effects, compared to people who had switched to efavirenz or nevirapine
From The New England Journal of Medicine (September 11, 2003)